Clinical trial · Interventional
Effect of Quercetin in Prevention and Treatment of Oral Mucositis
Effect of Quercetin in Prevention and Treatment of Chemotherapy Induced Oral Mucositis in Blood Dyscrasias
NCT01732393CI-TRIAL-00008600completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to evaluate the effect of Quercetin (a natural flavonoid) on prevention of and treatment of chemotherapy-induced oral mucositis in patients with blood malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Induced Oral Mucositis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| oral quercetin capsules | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- oral quercetin capsules
- description
- Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
- interventionNames
- Drug: oral quercetin capsules
- type
- PLACEBO_COMPARATOR
- label
- oral placebo capsules
- description
- Patients in the placebo group received two placebo capsules containing lactose .
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- lower grade of mucositis
- timeFrame
- 3 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * patient under chemotherapy * for a hematologic malignancy * the hematologist permits the trial on the patient * agreement of patient for participating in the trial Exclusion Criteria: * presence pf ANY oral lesion at the beginning of the trial * loss of follow up * use of digoxin and cyclosporine * patient death
References
Publications (0)
Data not yet available
No reference posted for this study.